These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 35017046)

  • 1. Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment.
    Rizzo MR; Di Meo I; Polito R; Auriemma MC; Gambardella A; di Mauro G; Capuano A; Paolisso G
    Pharmacol Res; 2022 Feb; 176():106062. PubMed ID: 35017046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective Effect of SGLT2 Inhibitors.
    Pawlos A; Broncel M; Woźniak E; Gorzelak-Pabiś P
    Molecules; 2021 Nov; 26(23):. PubMed ID: 34885795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes and Cardiorenal Complications: A Clinical Review of Existing Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors.
    Kale A; Sharma A; Anders HJ; Gaikwad AB
    Curr Diabetes Rev; 2023; 19(8):e160822207546. PubMed ID: 35975848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.
    Liu Z; Ma X; Ilyas I; Zheng X; Luo S; Little PJ; Kamato D; Sahebkar A; Wu W; Weng J; Xu S
    Theranostics; 2021; 11(9):4502-4515. PubMed ID: 33754074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.
    Neumiller JJ; White JR; Campbell RK
    Drugs; 2010 Mar; 70(4):377-85. PubMed ID: 20205482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus.
    Lukic N; Macvanin MT; Gluvic Z; Rizzo M; Radak D; Suri JS; Isenovic ER
    Curr Med Chem; 2024; 31(30):4781-4806. PubMed ID: 37855338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Use of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors and Cognitive Function in a Longitudinal Study of Patients with Type 2 Diabetes.
    Low S; Goh KS; Ng TP; Moh A; Ang SF; Wang J; Ang K; Tang WE; Lim Z; Subramaniam T; Sum CF; Lim SC
    J Alzheimers Dis; 2022; 87(2):635-642. PubMed ID: 35342091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D; Javor E; Lucijanić T; Skelin M
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrovascular Complications of Diabetes: SGLT-2 Inhibitors as a Promising Future Therapeutics.
    Chavda V; Vashi R; Patel S
    Curr Drug Targets; 2021; 22(14):1629-1636. PubMed ID: 33081674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment.
    D'Onofrio N; Sardu C; Trotta MC; Scisciola L; Turriziani F; Ferraraccio F; Panarese I; Petrella L; Fanelli M; Modugno P; Massetti M; Marfella LV; Sasso FC; Rizzo MR; Barbieri M; Furbatto F; Minicucci F; Mauro C; Federici M; Balestrieri ML; Paolisso G; Marfella R
    Mol Metab; 2021 Dec; 54():101337. PubMed ID: 34500107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
    Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects.
    Palmiero G; Cesaro A; Vetrano E; Pafundi PC; Galiero R; Caturano A; Moscarella E; Gragnano F; Salvatore T; Rinaldi L; Calabrò P; Sasso FC
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic Communication by SGLT2 Inhibition.
    Billing AM; Kim YC; Gullaksen S; Schrage B; Raabe J; Hutzfeldt A; Demir F; Kovalenko E; Lassé M; Dugourd A; Fallegger R; Klampe B; Jaegers J; Li Q; Kravtsova O; Crespo-Masip M; Palermo A; Fenton RA; Hoxha E; Blankenberg S; Kirchhof P; Huber TB; Laugesen E; Zeller T; Chrysopoulou M; Saez-Rodriguez J; Magnussen C; Eschenhagen T; Staruschenko A; Siuzdak G; Poulsen PL; Schwab C; Cuello F; Vallon V; Rinschen MM
    Circulation; 2024 Mar; 149(11):860-884. PubMed ID: 38152989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome.
    Akiyama H; Nishimura A; Morita N; Yajima T
    Front Endocrinol (Lausanne); 2023; 14():1111984. PubMed ID: 36793276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ertugliflozin for the treatment of type 2 diabetes.
    Sharma R; Razdan K; Kuhad A; Kuhad A
    Drugs Today (Barc); 2019 Mar; 55(3):167-175. PubMed ID: 30938372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential anti-arrhythmic effect of SGLT2 inhibitors.
    Duan HY; Barajas-Martinez H; Antzelevitch C; Hu D
    Cardiovasc Diabetol; 2024 Jul; 23(1):252. PubMed ID: 39010053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
    Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
    Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. State-of-the-Art-Review: Mechanisms of Action of SGLT2 Inhibitors and Clinical Implications.
    Vallon V
    Am J Hypertens; 2024 Oct; 37(11):841-852. PubMed ID: 39017631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.